Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2017 07:00 ET | Source: Bellicum Pharmaceuticals

Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association

MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
June 23, 2017 07:00 ET | Source: Bellicum Pharmaceuticals

Bellicum Reports Clinical Results of BPX-501 in Pediatric Leukemias at the 22nd Congress of the European Hematology Association

MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
May 31, 2017 07:00 ET | Source: Bellicum Pharmaceuticals

Bellicum Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference

HOUSTON, May 31, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
May 18, 2017 07:00 ET | Source: Bellicum Pharmaceuticals

Bellicum Announces Clinical Presentations at the 22nd Congress of the European Hematology Association

Overall-cohort abstract on BPX-501 selected for presentation at Presidential Symposium Oral and poster presentations highlight BPX-501 data in leukemias and hemoglobinopathies HOUSTON, May 18, 2017...
May 15, 2017 16:30 ET | Source: Bellicum Pharmaceuticals

Bellicum Pharmaceuticals Announces Management Changes

HOUSTON, May 15, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
May 08, 2017 16:05 ET | Source: Bellicum Pharmaceuticals

Bellicum Pharmaceuticals Reports First Quarter 2017 Financial Results

HOUSTON, May 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
April 26, 2017 07:00 ET | Source: Bellicum Pharmaceuticals

Bellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference

HOUSTON, April 26, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
April 04, 2017 08:00 ET | Source: Bellicum Pharmaceuticals

Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR-T / TCR Technology at AACR

HOUSTON, April 04, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
March 30, 2017 07:00 ET | Source: Bellicum Pharmaceuticals

Bellicum Pharmaceuticals Announces Closing of Public Offering

HOUSTON, March 30, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the closing, on March 29, 2017, of its previously announced underwritten public offering of...
March 23, 2017 18:20 ET | Source: Bellicum Pharmaceuticals

Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

HOUSTON, March 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a...